Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada’s First Generic Thyroid Medication
Genix Pharmaceuticals Corporation prepares to file Abbreviated New Drug Submissions (ANDS) for its first ten Ophthalmic Drugs with Health Canada
Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and closing of acquisition of rights to Nutraceutical Products Sucanon® and Renochlor®
Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private Placement
Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor®, Sucanon® and Flu-x™
Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)
Genix Pharmaceuticals Corporation Completes Purchase of Rights to 30 Ophthalmic Generic Drugs and Product Dossiers
